About the Company

Aurinia Pharmaceuticals (TSX: AUP, NasdaqGM: AUPH) is a clinical stage biopharmaceutical company developing voclosporin as a potential best-in-class calcineurin inhibitor (CNI) for the treatment for patients with lupus nephritis (LN). Members of Aurinia’s management team have extensive clinical experience in the development of treatments for lupus, and are leveraging this know-how for the development of voclosporin. A randomized, double-blind, Phase IIb trial is currently enrolling and is expected to complete enrollment in the third quarter of 2015.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research